Baidu
map

BMC Complement Altern Med:中药玉屏风散对成年人过敏性鼻炎治疗效果的研究

2017-11-20 AlexYang MedSci原创

中药玉屏风散(YPFS)经常用于过敏性鼻炎(AR)的治疗。之前的综述总结了YPFS的治疗效果和安全性,然而却没有亚群的分析来提供指导临床实践的详细证据。YPFS在中药临床实践指南中推荐作为治疗AR的药物,但是YPFS的治疗时间并没有特别的陈述。最近,有研究人员进行了旨在评估YPFS在治疗成年人AR中的效果和安全性的研究,并利用了最新的证据,并且还在亚群元分析中尝试确定YPFS的使用时间。研究发现,

中药玉屏风散(YPFS)经常用于过敏性鼻炎(AR)的治疗。之前的综述总结了YPFS的治疗效果和安全性,然而却没有亚群的分析来提供指导临床实践的详细证据。YPFS在中药临床实践指南中推荐作为治疗AR的药物,但是YPFS的治疗时间并没有特别的陈述。最近,有研究人员进行了旨在评估YPFS在治疗成年人AR中的效果和安全性的研究,并利用了最新的证据,并且还在亚群元分析中尝试确定YPFS的使用时间。

研究发现,22个随机对照试验(RCTs)总共包括了23个比较。YPFS与安慰剂、药物疗法进行了比较,并且作为一种附加的治疗与药物治疗进行了比较。元分析对4个鼻症状得分和"有效率"是可行的。另外,在YPFS组合治疗之后,4个鼻症状得分表现为降低:鼻痒(MD-0.46, 95% CI[-0.50, -0.42])、打喷嚏(MD-0.41, 95% CI[-0.47, -0.35])、鼻塞((MD-0.46, 95% CI[-0.54, -0.39])和流鼻涕(MD-0.42, 95% CI[-0.58, -0.26])。基于"有效率",元分析表明了YPFS并没有比单独的药物治疗具有更好的效果(RR1.07, 95%CI [0.94, 1.22]),但是YPFS与药物的组合使用要比单独的药物治疗更为有效(RR1.27, 95%CI [1.19, 1.34])。亚群分析表明YPFS并不比第二代抗组胺剂更好(RR1.04, 95%CI [0.90, 1.19])。更进一步的是,当使用时间超过3周时,YPFS的组合治疗效果更好((RR1.15, 95%CI [1.01, 1.32])。另外,YPFS对成年人AR具有很好的耐受性。最后,研究人员指出,中药YPFS对成年人AR是有益的。潜在的益处需要通过更多严谨的RCTs来进行评估。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2018-02-27 xuyong536
  3. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2018-07-03 仁者大医
  5. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2017-12-06 shizhenshan
  6. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2018-06-11 w363522449
  7. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2018-09-15 zsyan
  8. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2017-11-30 往日如昨

    学习了谢谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]

相关资讯

中药如何告别“尚不明确”时代

近日,对马兜铃酸与肝癌相关性的热议引发了民众关注。马兜铃酸安全性问题,也将中药的安全问题推向了风口浪尖。

中医中药中国行走进福建:唱响八闽中医药好声音

10月26日,“中医中药中国行——福建省中医药健康文化推进行动”暨“晋江市名医工作站”启动仪式在福建省泉州晋江市举行。

国家卫计委:发展中医药特色医养 鼓励社会资本进入

11月15日,国家卫生计生委发布了《“十三五”健康老龄化规划重点任务分工》的通知(下称《通知》),明确指出了包含国家卫生计生委等在内在13部门关于“十三五”健康老龄化规划重点任务的分工。

炸开锅!这些药致肝癌?

近日,一篇关于马兜铃酸的论文,在权威医学期刊《Science Translation Medicine》上,并荣登该杂志封面。这篇探讨马兜铃酸与肝癌关系的论文,瞬间在全社会炸开了锅。 ▍天造地设的“理想毒药”? 说起马兜铃酸,早在1993年,马兜铃酸就作为肾衰竭元凶被人们所认识,只需要130毫克的马兜铃酸就可以导致肾病。 而本次上封面的,是来自新加坡和台湾的研究人员的

中药攻占全球,80个国家动起来了

“太激动人心了!中药攻占全球市场,我们有希望!”出席 “世界中医药服务贸易联合会”成立大会的一位代表发出了内心的感慨。日前,中国医药物资协会在加勒比海洋量子号游轮上主办的第十二届中国成长型医药企业发论坛暨世界中医药服务贸易推进大会上,5000名医药人士出席。在这次活动上,自全球80多个国家和地区的中医药行业代表共同发起成立了世界中医药服务贸易联合会。在中国倡导的“一带一路”获世界瞩目背景下,中药通

中药注射剂、生化药大检查!

昨日(11月10日),黑龙江省药监局印发《黑龙江省2017年生化药品及中药注射剂专项检查工作方案》(以下简称方案),将对全省所有生化药品及中药注射剂药品生产企业进行检查。

Baidu
map
Baidu
map
Baidu
map